RedHill Biopharma Ltd.
RDHL
Price:
$10.89
Market Cap:
$13.88M
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in P...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2013-01-07
Stock Exchange
NASDAQ
Ticker
RDHL
The PE Ratio as of September 2024 (TTM) for RedHill Biopharma Ltd. (RDHL) is -0.04
According to RedHill Biopharma Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.04. This represents a change of -100.23% compared to the average of 17.45 of the last 4 quarters.
RedHill Biopharma Ltd. (RDHL) Historical PE Ratio (quarterly & annually)
How has RDHL PE Ratio performed in the past?
The mean historical PE Ratio of RedHill Biopharma Ltd. over the last ten years is -88.57. The current -0.04 PE Ratio has changed -95.48% with respect to the historical average. Over the past ten years (40 quarters), RDHL's PE Ratio was at its highest in in the March 2014 quarter at 215.63. The PE Ratio was at its lowest in in the September 2015 quarter at -300.38.
Average
-88.57
Median
-82.14
Minimum
-269.47
Maximum
9.89
RedHill Biopharma Ltd. (RDHL) PE Ratio by Quarter and Year
Discovering the peaks and valleys of RedHill Biopharma Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 65.46%
Maximum Annual PE Ratio = 9.89
Minimum Annual Increase = -369.65%
Minimum Annual PE Ratio = -269.47
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | 9.89 | -369.65% |
| 2022 | -3.67 | -86.03% |
| 2021 | -26.25 | -68.24% |
| 2020 | -82.66 | -19.95% |
| 2019 | -103.26 | 26.52% |
| 2018 | -81.62 | 65.46% |
| 2017 | -49.33 | -55.22% |
| 2016 | -110.16 | -34.89% |
| 2015 | -169.19 | -37.21% |
| 2014 | -269.47 | 55.63% |
RedHill Biopharma Ltd. (RDHL) Average PE Ratio
How has RDHL PE Ratio performed in the past?
The current PE Ratio of RedHill Biopharma Ltd. (RDHL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.68
5-year avg
-41.19
10-year avg
-88.57
RedHill Biopharma Ltd. (RDHL) PE Ratio vs. Peers
How is RDHL’s PE Ratio compared to its peers?
RedHill Biopharma Ltd.’s PE Ratio is greater than Organogenesis Holdings Inc. (-49.69), less than Lifecore Biomedical, Inc. (13.00), less than Taro Pharmaceutical Industries Ltd. (29.99), less than Collegium Pharmaceutical, Inc. (12.02), greater than Aquestive Therapeutics, Inc. (-17.59), greater than Evoke Pharma, Inc. (-0.88), greater than Adamis Pharmaceuticals Corporation (-0.47), greater than Guardion Health Sciences, Inc. (-2.17), greater than AcelRx Pharmaceuticals, Inc. (-1.83), greater than Petros Pharmaceuticals, Inc. (-0.22), greater than Cumberland Pharmaceuticals Inc. (-1.77), greater than Agile Therapeutics, Inc. (-0.65), greater than PainReform Ltd. (-0.18), greater than China Pharma Holdings, Inc. (-0.73), less than Halo Collective Inc. (-0.00), greater than Alimera Sciences, Inc. (-20.50), less than China SXT Pharmaceuticals, Inc. (-0.02), greater than Alpha Teknova, Inc. (-5.21), greater than Cyclo Therapeutics, Inc. (-0.94),
| Company | PE Ratio | Market cap |
|---|---|---|
| -49.69 | $377.84M | |
| 13.00 | $157.89M | |
| 29.99 | $1.62B | |
| 12.02 | $1.19B | |
| -17.59 | $453.02M | |
| -0.88 | $3.47M | |
| -0.47 | $7.25M | |
| -2.17 | $12.79M | |
| -1.83 | $14.58M | |
| -0.22 | $3.64M | |
| -1.77 | $18.32M | |
| -0.65 | $10.43M | |
| -0.18 | $1.07M | |
| -0.73 | $3.42M | |
| -0.00 | $895.00 | |
| -20.50 | $301.29M | |
| -0.02 | $2.15M | |
| -5.21 | $232.93M | |
| -0.94 | $19.60M |
Build a custom stock screener for RedHill Biopharma Ltd. (RDHL) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RedHill Biopharma Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
RedHill Biopharma Ltd. (RDHL) and other stocks custom spreadsheet templates
The easiest way to analyze a company like RedHill Biopharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is RedHill Biopharma Ltd.'s PE Ratio?
How is the PE Ratio calculated for RedHill Biopharma Ltd. (RDHL)?
What is the highest PE Ratio for RedHill Biopharma Ltd. (RDHL)?
What is the 3-year average PE Ratio for RedHill Biopharma Ltd. (RDHL)?
What is the 5-year average PE Ratio for RedHill Biopharma Ltd. (RDHL)?
How does the current PE Ratio for RedHill Biopharma Ltd. (RDHL) compare to its historical average?